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Abstract : Postoperative atrial brillation（AF）is associated with signicant morbid-
ity after cardiac surgery.  We examined the effects of a prophylactic postoperative 
amiodarone infusion to prevent postoperative AF.  A prospective randomized study 
was performed in patients with a high risk of postoperative AF between March 
2016 and March 2019.  High risk of AF was dened as combined valve surgery, 
aortic valve replacement（age＞ 70）, or off-pump coronary bypass grafting（age＞
65）.  Forty-two patients were enrolled and randomly assigned to receive prophy-
lactic amiodarone infusion（amiodarone group, n＝20）or saline infusion（control 
group, n＝22）.  In the amiodarone group, amiodarone was infused intravenously 
for 48 hr postoperatively（initially 125 mg/10 min, then 288 mg/6 hr, then mainte-
nance of 1,040 mg/42 hr）.  There were no signicant differences between the two 
groups in age, sex, body height, body weight, surgical procedure, and perioperative 
use of beta blockers.  The occurrence of sustained AF for＞ 1 hr was signicantly 
lower in the amiodarone group（30.0％）than in the control group（63.6％,  
p＝0.04）.  The total duration of AF over one week was also signicantly shorter 
in the amiodarone group（296.8 ± 676.9 min）than in the control group（921.4 ±
1641.6 min, p＝0.04）, as was the postoperative hospital stay（17.3 ± 6.1 vs. 24.5 ± 11.3 
days, respectively, p＝0.01）.  There were no major side effects with amiodarone 
infusion except for one case of bradycardia.  These results show the prophylactic 
use of intravenous amiodarone infusion for the first 48 hr of the postoperative 
period is a safe and effective treatment to prevent postoperative AF after cardiac 
surgery and to shorten the hospital stay.
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Introduction
　Postoperative atrial fibrillation（AF）has an incidence of 30％-50％ after cardiac surgery1-3）. 
Postoperative AF occurs most frequently on postoperative day two and recurs 40％ of the 
time4，5）.  Postoperative AF is associated with increased morbidity and mortality and longer, more 
expensive hospital stays6-8）.
　The American Heart Association / American College of Cardiology / Heart Rhythm Society 
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guidelines have already recommended the preoperative administration of amiodarone to reduce the 
incidence of AF（Class Ⅱa）9）.  Furthermore, several clinical studies have evaluated the preoperative 
use of amiodarone（oral and intravenous use）for the prevention of postoperative AF10-19）; 
however, a disadvantage of this method is that it requires intensive monitoring for the occurrence 
of bradycardia caused by amiodarone use.  
　An advantage of the postoperative use of intravenous amiodarone for 48 hr is that 
postoperative AF occurs most frequently on postoperative day two 4，5）; thus, the concentration 
of amiodarone would be in the effective range during this period.  Furthermore, because 
a temporary pacing wire is routinely implanted on the right ventricle during the operation, 
bradycardia caused by amiodarone infusion can be safely managed by temporary pacing in the 
intensive care unit（ICU）.  Consequently, there is less additional burden for perioperative care 
due to postoperative prophylaxis compared with preoperative amiodarone use.
　The aim of this study was to clarify whether intravenous amiodarone administration only 
during the immediate 48 hr post-surgery period is effective for the prevention of postoperative 
AF.
Patients and methods
　This study was approved by the Institutional Review Board of the Showa University Hospital
（Permit Number: 1451081）.  
　This prospective randomized study was conducted between March 2016 and March 2019.  The 
154 patients who underwent open cardiac surgery during this period were screened, and 132 
of these patients had elective operations.  Sixty-five patients were excluded due to prior AF
（n＝49）, pacemaker implantation（n＝5）, sick sinus syndrome（n＝1）, complete left bundle 
branch block（n＝1）, or hemodialysis（n＝9）.  We selected high-risk patients for our cohort 
according to previous studies to prove the effectiveness of our procedure.  Several preoperative 
factors including age, dilatation of the left atrium, and left ventricular hypertrophy carry high 
associations with the occurrence of postoperative AF; likewise, some intraoperative factors such 
as surgical or ischemic injuries to the atrium and pulmonary veins caused by cannulation have 
high associations20，21）.  Therefore, combined valve surgery was considered to have a high risk 
of postoperative AF, in addition to aortic valve replacement and off-pump coronary bypass 
grafting in elderly patients.  High risk of AF was defined as combined valve surgery, aortic valve 
replacement（＞ 70 years old）, or off-pump coronary bypass grafting（＞ 65 years old）.  Forty-
four of the eligible patients were classified in the high-risk AF group.  Two patients refused 
to enroll in the study.  The remaining 42 patients gave both verbal and written consent to 
participate in the trial.  They were randomly divided into two groups: amiodarone group（n＝
20）and control group（n＝22）（Fig. 1）.  For the patients in the amiodarone group, amiodarone 
was infused intravenously for 48 hr at the following rates : initial rapid infusion（125 mg/10 min）, 
loading dose（288 mg/6 hr）, and maintenance dose（1,040 mg/42 hr）; administration began just 
after transportation to the ICU after surgery.
　We used 24-hr continuous electrocardiogram monitoring during the first postoperative week 
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and defined AF as a continuous AF waveform for more than 5 min.  The occurrence of sustained 
AF for more than one hr, total duration of AF over one week, postoperative hospital stay period, 
and required treatments were compared between the two groups.  We used Fisher’s exact test for 
categorical variables and the Wilcoxon rank sum test for continuous variables.  Values of p＜0.05
（two-sided test for Fisher’s exact test）were considered significant.
Results
　There were no significant differences in age, sex, body height, body weight, or preoperative 
use of beta blockers between the two groups（Table 1）.  Additionally, there were no significant 
differences in surgical procedures between the two groups（Table 1）.  
　The occurrence of sustained AF for＞ 1 hr was significantly lower in the amiodarone group 
than in the control group（30.0％ vs. 63.6％, respectively ; p＝0.04）.  Additionally, the total 
duration of AF during the one week after surgery was significantly shorter in the amiodarone 
group than in the control group（296.8 ± 676.9 vs. 921.4 ± 1641.6 min, respectively; p＝0.04）.  The 
frequency of postoperative beta blocker administration tended to be lower in the amiodarone 
group（30.0％ vs. 59.1％, respectively ; p＝0.07）; likewise, the frequency of antiarrhythmic drug 
use tended to be lower in the amiodarone group（20.0％）than in the control group（50.0％, 
p＝0.06）.  There were no significant differences in which postoperative day the first episode 
of AF occurred, recurrence of AF, direct current defibrillation for AF, or anticoagulant therapy 
Fig. 1.   Study flowchart. AF: atrial fibrillation, SSS: sick sinus syndrome, 
CLBBB: complete left bundle branch block, AVR: aortic valve 
replacement, OPCAB: off-pump coronary artery bypass
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for AF between the two groups（Tables 2, 3）.  However, the postoperative hospital stay was 
significantly shorter in the amiodarone group than in the control group（17.3 ± 6.1 vs. 24.5 ± 11.3 
days, respectively; p＝0.01）.  Only one patient was discharged within two weeks after surgery in 
the control group, whereas seven patients were discharged within two weeks in the amiodarone 
group.  Thus, significantly fewer patients in the amiodarone group had a hospital stay of more 
than two weeks compared to the control group（65.0％ vs. 95.5％, respectively; p＝0.02）.  The 
30-day mortality rate was 0％ in both groups.  There was one case of stroke in the control 
group（Table 4）, and there was one case of bradycardia（50 bpm, postoperative day 0）in the 
Table 1.  Patient characteristics
Amiodarone（n＝20） Control（n＝22） p-value
Age（years） 75.4 ± 8.1     76.6 ± 7.0 0.58
Sex（male） 13（65.0） 10（45.5） 0.23
Body height（cm） 157.3 ± 10.2   154.7 ± 9.5 0.31
Body weight（kg） 57.4 ± 9.2 57.3 ± 13.2 0.48
Preoperative beta blockers  6（30.0） 12（54.6） 0.13
Type of surgery
・Combined valve surgery  2（10.0）  7（31.8） 0.14
・AVR 11（55.0） 11（50.0） 0.77
・OPCAB  7（35.0）  4（18.2） 0.30
Data are expressed as mean ± standard deviation or as the number of patients（％）.
AVR: aortic valve replacement, OPCAB: off-pump coronary artery bypass.
Table 2.  Atrial fibrillation（AF）study endpoints
Amiodarone（n＝20） Control（n＝22） p-value
Occurrence of sustained AF＞ 1 hr 6（30.0） 14（63.6） 0.04
Total duration of AF over one week（min） 296.8 ± 676.9 921.4 ± 1641.6 0.04
Postoperative beta blockers 6（30.0） 13（59.1） 0.07
Antiarrhythmic medications for AF 4（20.0） 11（50.0） 0.06
DC for AF 3（15.0）  5（22.7） 0.70
Anticoagulant therapy for AF 1（5.0）  4（18.2） 0.35
Data are expressed as the number of patients（％）.
DC: direct current defibrillation
Table 3.  Clinical outcomes of patients with atrial fibrillation（AF）
Amiodarone（n＝ 7） Control（n＝ 14） p-value
Time to first episode of AF（POD） 3.4 ± 1.3 2.7 ± 1.6 0.11
Recurrence of AF 3（42.9） 12（85.7） 0.12
Data are expressed as mean ± standard deviation or as the number of patients（％）.
POD: postoperative day
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amiodarone group.  Amiodarone infusion caused no major side effects, such as hypotension
（systolic blood pressure＜ 80 mmHg）or liver dysfunction（transaminase＞ 100 units/dl）.
Discussion
　There were two major findings in this study: ［1］ the use of amiodarone infusion for 48 hr 
postoperatively prevented postoperative sustained AF for more than one hr, and ［2］ the hospital 
stay period after surgery was significantly shorter in the amiodarone group.
　Although previous studies have shown the effectiveness of amiodarone for the prevention 
of AF10-19，22-24）, the clinical use of amiodarone lacked standardization.  The American Heart 
Association / American College of Cardiology / Heart Rhythm Society guidelines recommend 
the preoperative oral use of amiodarone 9）.  However, intravenous use has several advantages 
compared to oral administration25）（Table 5）.  First, intravenous amiodarone has little effect 
on heart rate during sinus rhythm, and the frequency of sinus bradycardia is low.  Moreover, 
it does not prolong the QTc duration.  Second, it has minimal antithyroid action.  Third, the 
bioavailability of oral amiodarone is approximately 35％ to 65％, and the oral form requires 
several days until the onset of antiarrhythmic action.  Conversely, the bioavailability of 
intravenous amiodarone is 100％, the onset of action is fast, and intravenous amiodarone can be 
used in the ICU immediately after surgery.
　Amiodarone has been associated with multiple organ toxicity issues involving the lungs, 
Table 4.  Incidence of major morbidity, mortality and postoperative hospital stay
Amiodarone（n＝20） Control（n＝22） p-value
Cerebrovascular accidents 0 1（4.5）＊ 1.00
30-day mortality 0 0
Postoperative hospital stay（days） 17.3 ± 6.1 24.5 ± 11.3 0.01
Over 2-week postoperative stay 13（65.0） 21（95.5） 0.02
Data are expressed as mean ± standard deviation or as the number of patients（％）.  
＊Cerebrovascular accident was a stroke.
Table 5.  The differences between oral and intravenous amiodarone＊
Oral amiodarone Intravenous amiodarone
Slowing of phase 4 depolarisation in the sinus node ＋＋＋ ＋
Heart rate ↓↓ - /↓
QTc duration ↑↑↑ - /↑
Interaction with the thyroid axis
（block conversion of thyroxine to triiodothyronine） ＋＋＋ -
Bioavailability 35％～ 65％ 100％
Onset of antiarrhythmic action delay rapid
＋ ; yes or present, - ; no or absent, ↑; increase, ↓; decrease.
＊Taken from Desai AD, et al. Ann Intern Med. 1997（Ref # 25）.
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thyroid, and liver ; these side effects are related to the total amount of amiodarone exposure, 
i.e., dosage and treatment duration 25，26）.  Therefore, the prophylactic use of amiodarone should 
be the lowest effective dosage possible for the shortest effective duration.  Most of the side 
effects involving multiple organ systems are thought to be minimal with short-term intravenous 
therapy25）.  Additionally, studies have shown that postoperative AF occurs most frequently on 
postoperative day two4，5）.  Using our method, the concentration of amiodarone would be in the 
effective range during this period.  Thus, the 48-hr use after the operation in the ICU is a safe 
and effective usage of intravenous amiodarone.
　This study has several limitations.  First, the cohort was comprised only of patients with 
a high risk of AF, which we have defined.  A randomized trial with all open-heart surgery 
patients might have shown more advantages because we had very few side effects caused by our 
protocol.  Second, the study size was rather small.  The difference in the occurrence of AF（p＝
0.12）might have reached statistical significance in a larger study; however, we believe that the 
effectiveness of the 48-hr use of amiodarone can be demonstrated by the reduced occurrence of 
sustained AF for more than 1 hr and the shorter total duration of AF during one week.
Conclusions
　The prophylactic use of intravenous amiodarone infusion only during the immediate 
postoperative period is a safe and effective treatment to prevent postoperative AF and it shows 
benefits in shortening the hospital stay.
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